| DB ID | MyCo_1321 |
| Title | Comparison of β-1-3-D-Glucan and Candida Mannan Biomarker Assays with Serological Tests for the Diagnosis of Candidemia |
| Year | 2023 |
| PMID | 37623584 |
| Fungal Diseases involved | Candidemia |
| Associated Medical Condition | None |
| Genus | Candida |
| Species | albicans |
| Organism | Candida albicans |
| Ethical Statement | Ethical review and approval were waived for this study as data were based on residual patient samples (obtained in the course of standard clinical care) for the purposes of laboratory assay evaluation and validation. |
| Site of Infection | None |
| Opportunistic invasive | Opportunistic |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | Germ tube antibody (CAGTA) |
| Biomarker Full Name | Germ tube antibody (CAGTA) |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | UK |
| Cohort | Serum samples from 14 patients with proven or probable invasive candidiasis, and from 10 control patients, were included in the analysis. Serum samples (n = 866), taken between March 2013 and July 2016, for BDG assay were identified retrospectively from the database of the Mycology Reference Centre Manchester (MRCM), Wythenshawe Hospital, Manchester, UK. |
| Cohort No. | 14 Patients and 10 Control |
| Age Group | None |
| P Value | None |
| Sensitivity | 0.57 |
| Specificity | 0.6 |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Invasive candidiasis, including candidemia, encompasses the most serious manifestations of Candida infection. It is the most common invasive fungal disease globally. Candidemia is particularly common among critically ill patients receiving antimicrobials and is associated with a significant mortality risk. The diagnosis of candidemia may be challenging, primarily due to a low yield from blood culture specimens and the inconsistent performance of molecular techniques across different patient populations. |
| Technique | Immunological assay |
| Analysis Method | C. albicans germ tube antibody (CAGTA) assay (Vircell) |
| ELISA kits | None |
| Assay Data | None |
| Validation Techniques used | C. albicans germ tube antibody (CAGTA) assay (Vircell) |
| Up Regulation Down Regulation | None |
| Sequence Data | None |
| External Link | None |
